An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer

Yu Katayose, Hideo Ohtsuka, Yo Kitamura, Kunihiro Masuda, Kei Nakagawa, Kuniharu Yamamoto, Hiroshi Yoshida, Tohru Onogawa, Fuyuhiko Motoi, Takeshi Naitoh, Toshiki Rikiyama, Shin Ichi Egawa, Michiaki Unno

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Background/Aims: Gemcitabine is widely used as a first-line therapy for biliary tract cancer (BTC). However, few studies have been conducted to analyze second-line therapies. Methodology: From 33 patients who had been administered gemcitabine following resection between May 2005 and August 2007, we retrospectively analyzed the safety and efficacy of S-1 in 11 cases who received S-1 as second-line therapy due to recurrence or relapse of the primary disease. Results: Among the adverse events (AEs) observed during S-1 administration, the most common was a decrease in the concentration of hemoglobin, followed by thrombocytopenia. No Grade 4 AEs or worse were detected. In addition, the AEs and their respective severity strongly resembled those of gemcitabine used as a first-line therapy. There were 7 cases that could be evaluated according to RECIST criteria, of which 1 was considered in the partial response and 3 as stable disease. The medians of time to progression after S-1 administration and survival after S-1 administration were 5.6 months and 31 months, respectively. Conclusions: S-1 could be taken safely as a second-line therapy without provoking severe AEs. By preventing the cessation of S-1 administration due to its AEs, more continued S-1 administration could lead to a better prognosis for BTC.

Original languageEnglish
Pages (from-to)691-695
Number of pages5
Issue number115
Publication statusPublished - 2012 May


  • Biliary tract cancer
  • Chemotherapy
  • S-1
  • Second line

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer'. Together they form a unique fingerprint.

Cite this